

Magdalena Maria Jankowska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3560185/publications.pdf>

Version: 2024-02-01

31
papers

413
citations

933447

10
h-index

794594

19
g-index

31
all docs

31
docs citations

31
times ranked

615
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of thyroid nodules in early stage autosomal polycystic kidney disease. BMC Nephrology, 2022, 23, 85.	1.8	1
2	Ambulatory pulse pressure and its contributors in autosomal dominant polycystic kidney disease. Advances in Clinical and Experimental Medicine, 2022, 31, 0-0.	1.4	0
3	MO576ASSOCIATION OF BONE MATERIAL STRENGTH WITH BONE DENSITY IN PATIENTS WITH END-STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
4	Comparative studies on vitamin B1 deficiency in whole blood of chronically haemodialysed patients: chromatographic, fluorimetric and PCA study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1180, 122880.	2.3	0
5	CD5-Positive B Lymphocytes after Kidney Transplantation. Diagnostics, 2021, 11, 1574.	2.6	1
6	Early outcomes and long-term survival after kidney transplantation in elderly versus younger recipients from the same donor in a matched-pairs analysis. Medicine (United States), 2021, 100, e28159.	1.0	10
7	Vitamins in chronic kidney disease. , 2020, , 561-582.		0
8	SO037AMBULATORY BLOOD PRESSURE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE - IMPROVING DIAGNOSIS AND OPTIMIZING THERAPY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
9	Computation of the Texture Features on T2-Weighted Images as a Novel Method to Assess the Function of the Transplanted Kidney: Primary Research. Transplantation Proceedings, 2020, 52, 2062-2066.	0.6	7
10	Application of Total Kidney Volume and Its Predictive Value in Assessment of Kidney Transplant Waitlist Candidates With Autosomal Dominant Polycystic Kidney Disease. Transplantation Proceedings, 2020, 52, 2273-2277.	0.6	0
11	Vascular complications in patients with Autosomal Dominant Polycystic Kidney Disease. A review of the literature and current clinical recommendations. European Journal of Translational and Clinical Medicine, 2020, 3, 64-71.	0.1	0
12	Amino acid profile after oral nutritional supplementation in hemodialysis patients with protein-energy wasting. Nutrition, 2019, 57, 231-236.	2.4	14
13	A distinct bone phenotype in ADPKD patients with end-stage renal disease. Kidney International, 2019, 95, 412-419.	5.2	23
14	MRI-derived markers for predicting a decline in renal function in patients with autosomal dominant polycystic kidney disease. Polish Journal of Radiology, 2019, 84, 289-294.	0.9	1
15	Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?. Nephrology, 2018, 23, 31-36.	1.6	2
16	Water soluble vitamins and peritoneal dialysis – State of the art. Clinical Nutrition, 2017, 36, 1483-1489.	5.0	13
17	Sclerostin – A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?. Kidney International Reports, 2017, 2, 481-485.	0.8	6
18	Thiamine Diphosphate Status and Dialysis-Related Losses in End-Stage Kidney Disease Patients Treated with Hemodialysis. Blood Purification, 2017, 44, 294-300.	1.8	23

#	ARTICLE	IF	CITATIONS
19	Impact of donor and recipient human cytomegalovirus status on kidney transplantation. <i>International Immunology</i> , 2017, 29, 541-549.	4.0	10
20	Inflammation and Protein-Energy Wasting in the Uremic Milieu. <i>Contributions To Nephrology</i> , 2017, 191, 58-71.	1.1	78
21	Vitamins and Microelement Bioavailability in Different Stages of Chronic Kidney Disease. <i>Nutrients</i> , 2017, 9, 282.	4.1	57
22	Biologically active form of vitamin B1 in human peritoneal effluent. <i>Advances in Clinical and Experimental Medicine</i> , 2017, 26, 1405-1410.	1.4	7
23	CD28 positive, cytomegalovirus specific cytotoxic T lymphocytes as a novel biomarker associated with cytomegalovirus viremia in kidney allograft recipients. <i>Journal of Clinical Virology</i> , 2016, 83, 17-25.	3.1	10
24	Skin cancer in kidney transplant recipients affected with autosomal dominant polycystic kidney disease. <i>Clinical Transplantation</i> , 2016, 30, 339-343.	1.6	4
25	Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease. <i>International Urology and Nephrology</i> , 2015, 47, 1739-1744.	1.4	12
26	Vitamin B6 and the Immunity in Kidney Transplant Recipients. , 2013, 23, 57-64.		9
27	Effects of Renal-specific Oral Supplementation in Malnourished Hemodialysis Patients. , 2011, 21, 347-353.		14
28	Immunosenescence increases the rate of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD4+ T-cells. <i>Mechanisms of Ageing and Development</i> , 2010, 131, 96-104.	4.6	63
29	Autosomal Dominant Polycystic Kidney Disease Is Not a Risk Factor for Post-transplant Diabetes Mellitus. Matched-pair Design Multicenter Study. <i>Archives of Medical Research</i> , 2008, 39, 312-319.	3.3	18
30	Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome. <i>Rheumatology International</i> , 2007, 27, 775-780.	3.0	17
31	Bioelectrical Impedance Analysis Before Versus After a Hemodialysis Session in Evaluation of Nutritional Status. , 2006, 16, 137-140.		13